opiodur 12micrograms/hour transdermal patches
pfizer ltd - fentanyl - transdermal patch - 12microgram/1hour
opiodur 75micrograms/hour transdermal patches
pfizer ltd - fentanyl - transdermal patch - 75microgram/1hour
opiodur 100micrograms/hour transdermal patches
pfizer ltd - fentanyl - transdermal patch - 100microgram/1hour
opiodur 50micrograms/hour transdermal patches
pfizer ltd - fentanyl - transdermal patch - 50microgram/1hour
fentadur 100 micrograms/hour transdermal patch 100 microgram per hour transdermal patch
pfizer healthcare ireland - fentanyl - transdermal patch - 100 microgram per hour
fentadur 25 micrograms/hour transdermal patch 25 microgram per hour transdermal patch
pfizer healthcare ireland - fentanyl - transdermal patch - 25 microgram per hour
fentadur 50 micrograms/hour transdermal patch 50 microgram per hour transdermal patch
pfizer healthcare ireland - fentanyl - transdermal patch - 50 microgram per hour
fentadur 75 micrograms/hour transdermal patch 75 microgram per hour transdermal patch
pfizer healthcare ireland - fentanyl - transdermal patch - 75 microgram per hour
fenpatch 100 fentanyl 100 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 16.5 mg - drug delivery system, transdermal - excipient ingredients: titanium dioxide; polypropylene; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.
fenpatch 75 fentanyl 75 mcg/hr transdermal patch pouch
medis pharma pty ltd - fentanyl, quantity: 12.375 mg - drug delivery system, transdermal - excipient ingredients: polypropylene; polyethylene terephthalate; titanium dioxide; ethyl acetate; 2-ethylhexyl acrylate/2-hydroxyethyl acrylate/methyl acrylate copolymer; hexane - for the management of pain associated with cancer, palliative care, and other conditions in patients where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.